GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms
Skin Appendage Disorders · 30.06.2026 · 1-9
DOI: 10.1159/000553070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Skin Appendage Disorders, online erschienen am 30.06.2026. Verfasst von Gerardo Uriel Viquez Burboa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hospital General Regional No. 2, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
GLP-1 receptor agonists (GLP-1 RAs) are among the fastest-growing pharmacological classes globally. Alopecia has emerged as a clinically relevant adverse effect signal, yet pooled quantitative estimates of risk by subtype and agent are lacking. The objective of this study was to estimate the pooled risk of alopecia associated with GLP-1 RA use, stratified by subtype, agent, and follow-up duration, and to synthesize mechanistic and management evidence.
Methods
PubMed/MEDLINE, Embase, Cochrane Central, Web of Science, and Scopus were searched from inception to March 31, 2026, with no language restrictions. Studies reporting alopecia outcomes in adult GLP-1 RA users were eligible, including cohort studies, pharmacovigilance disproportionality analyses, and case series (n ≥ 5). Of 1,847 identified records, 17 met eligibility criteria. Random-effects meta-analyses (DerSimonian-Laird) were performed for odds ratios (ORs) and reporting ORs (RORs). The protocol was prospectively registered in PROSPERO (CRD420261335458) and PRISMA 2020 guidelines were followed.
Results
Seventeen studies encompassing 1,091,743 patient-exposures were included. The pooled OR for any non-scarring alopecia was 1.40 (95% CI: 1.33–1.48; I2 = 0%; 3 cohort studies). Significant associations were found for telogen effluvium (aOR, 1.76; 95% CI: 1.34–2.32) and androgenetic alopecia (aOR, 1.64; 95% CI: 1.35–1.99) at 12 months; alopecia areata was not significant (aOR, 1.08; 95% CI: 0.87–1.34). Pharmacovigilance signals were highest for semaglutide (ROR, 2.46; 95% CI: 2.14–2.83) and tirzepatide (ROR, 1.73; 95% CI: 1.43–2.10). Paradoxically, 58% of patients with central centrifugal cicatricial alopecia showed improvement with GLP-1 RA use.
Conclusion
GLP-1 RAs are associated with a significant 40% increased risk of non-scarring alopecia, driven by telogen effluvium and androgenetic alopecia and primarily mediated by weight loss-induced micronutrient deficiency. Semaglutide and tirzepatide carry the highest pharmacovigilance burden. Dermatologists should counsel patients proactively, optimize nutrition, and avoid premature drug discontinuation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital General Regional No. 2, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico.
- Departamento de Salud Digital, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
Zitieren
APA
Viquez Burboa, G. U., Flores Guillén, M. Á. R., & Duardo González, V. S. (2026). GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disorders, 1-9. https://doi.org/10.1159/000553070
Vancouver
Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS. GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disorders. 2026:1-9. doi:10.1159/000553070
BibTeX
@article{ViquezBurboa2026,
author = {Viquez Burboa, Gerardo Uriel and Flores Guillén, Miguel Ángel Rafael and Duardo González, Vania Sofia},
title = {GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms},
journal = {Skin Appendage Disorders},
year = {2026},
pages = {1--9},
doi = {10.1159/000553070}
}
EUVIMED